CDKN2A and neoplasm: Finally, cladribine, which is a FDA-approved multiple sclerosis treatment drug, was selected and identified as a repurposable drug for treating melanoma with CDKN2A mutation by a comprehensive in vitro validation, serving as a demonstrating experimental protocol to utilize SLKG for novel tumor therapy discovery.